Abstract
The cannabinoid receptor CB2 is highly expressed in immune cells suggesting an important role in numerous diseases such as inflammation, cancer, osteoporosis and liver diseases relating to modulation of the immune system. As a consequence, activation of receptor CB2 is a promising therapeutic strategy for the treatment of a large range of diseases. Indeed, selective CB2 agonists display beneficial anti-inflammatory, anti-cancer and antifibrogenic properties and positive effects on liver disease and osteoporosis. This article reviews the CB2 involvement in the immune system and the promising therapeutical potential of selective CB2 agonists in the treatment of several immune-related diseases.
Keywords: Analgesic, anticancer, antifibrogenic, anti-inflammatory, cannabinoid receptors, CB2 agonists, immune system, immune-related diseases, liver disease, osteoporosis.
Current Molecular Pharmacology
Title:Therapeutical Potential of CB2 Receptors in Immune-Related Diseases
Volume: 6
Author(s): Natascha Leleu-Chavain, Pierre Desreumaux, Philippe Chavatte and Regis Millet
Affiliation:
Keywords: Analgesic, anticancer, antifibrogenic, anti-inflammatory, cannabinoid receptors, CB2 agonists, immune system, immune-related diseases, liver disease, osteoporosis.
Abstract: The cannabinoid receptor CB2 is highly expressed in immune cells suggesting an important role in numerous diseases such as inflammation, cancer, osteoporosis and liver diseases relating to modulation of the immune system. As a consequence, activation of receptor CB2 is a promising therapeutic strategy for the treatment of a large range of diseases. Indeed, selective CB2 agonists display beneficial anti-inflammatory, anti-cancer and antifibrogenic properties and positive effects on liver disease and osteoporosis. This article reviews the CB2 involvement in the immune system and the promising therapeutical potential of selective CB2 agonists in the treatment of several immune-related diseases.
Export Options
About this article
Cite this article as:
Leleu-Chavain Natascha, Desreumaux Pierre, Chavatte Philippe and Millet Regis, Therapeutical Potential of CB2 Receptors in Immune-Related Diseases, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/1874467207666140219122337
DOI https://dx.doi.org/10.2174/1874467207666140219122337 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
Call for Papers in Thematic Issues
Common mechanisms underpinning neurodevelopmental disorders and psychiatric diseases
A growing number of large-scale epidemiologic studies has strongly suggested that common mechanisms may be shared by aberrant brain development and psychiatric disorders. There is now an appreciation of synergic roles of genetic variants and environmental stress which profoundly affect the genome integrity and reshape brain development. This can lead ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Polycistronic Viral Vectors
Current Gene Therapy The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy
Current Cancer Drug Targets Optimal Saturated Neuropilin-1 Expression in Normal Tissue Maximizes Tumor Exposure to Anti-Neuropilin-1 Monoclonal Antibody
Anti-Cancer Agents in Medicinal Chemistry LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets 3D-QSAR and Docking Studies of 4-morpholinopyrrolopyrimidine Derivatives as Potent mTOR Inhibitors
Letters in Drug Design & Discovery Subject Index To Volume-3
Letters in Drug Design & Discovery NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP): Novel Regulators of Ca 2+-Signaling and Cell Function
Current Molecular Medicine Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology Gene Regulation in Cancer Gene Therapy Strategies
Current Medicinal Chemistry Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets